TROPION-Breast02
-
Datopotamab Deruxtecan Shows Unprecedented Survival Benefit in Metastatic Triple-Negative Breast Cancer
AstraZeneca and Daiichi Sankyo’s DATROWAY met dual primary endpoints in the TROPION-Breast02 Phase III trial for locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) patients. DATROWAY demonstrated a statistically significant and clinically meaningful improvement in both overall survival (OS) and progression-free survival (PFS) versus chemotherapy. The trial showed a 43% reduction in disease progression or death risk and a 5-month improvement in median OS versus chemotherapy. Detailed results will be presented at the 2025 ESMO Congress.
-
DATROWAY® Shows Unprecedented Five-Month Median Overall Survival Benefit vs. Chemotherapy in First-Line Treatment of Metastatic Triple-Negative Breast Cancer (TROPION-Breast02) for Patients Ineligible for Immunotherapy
The TROPION-Breast02 phase 3 trial, presented at ESMO 2025, shows DATROWAY significantly improved overall survival (OS) and progression-free survival (PFS) versus chemotherapy in locally recurrent inoperable or metastatic triple negative breast cancer (TNBC) patients ineligible for immunotherapy. DATROWAY reduced the risk of disease progression or death by 43% and improved median OS by 5 months. The objective response rate was 62.5% with DATROWAY versus 29.3% with chemotherapy, and median duration of response was 12.3 versus 7.1 months, respectively.
